Lawsuit Filed over Permanent Hair Loss with Taxotere Chemotherapy DrugAug 16, 2016
A recent lawsuit was filed on behalf of a California woman who suffered permanent hair loss, known as alopecia, allegedly due to using the chemotherapy drug Taxotere. The suit alleges that manufacturer Sanofi-Aventis failed to warn about the risk of permanent baldness while overstating the benefits of Taxotere compared to other alternatives.
The plaintiff was diagnosed with Stage II breast cancer in December 2010. Following surgery, she underwent six cycles of chemotherapy in 2011. Taxotere was used in the course of her chemotherapy treatment. According to her lawsuit, she did not realize that she had developed continuing hair loss related to Taxotere use until 2016.
Allegedly, thousands of patients were unfairly exposed to the risk of permanent baldness because the labeling on Taxotere is inadequate.
Sanofi-Aventis also allegedly obscured important safety data from the U.S. Food and Drug Administration (FDA). The plaintiff alleges eleven counts against the drug maker, including product liability for negligence, manufacturing defect, failure to warn and extreme and outrageous conduct/intentional infliction of emotional distress.
Taxotere is used to treat various types of cancer, including breast cancer. Taxotere, like other chemotherapy drugs, targets the rapid growth characteristic of cancer cells. These cancer treatments, however, also affect healthy, rapid growing cells in addition to malignant ones. Since hair follicles are among the fastest growing cells in the body, hair growth is affected by chemotherapy.